Corbus Pharmaceuticals
CRBP
122 hedge funds and large institutions have $103M invested in Corbus Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 50 increasing their positions, 33 reducing their positions, and 31 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 33
5% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $11.1M
0.2% more ownership
Funds ownership: 2.1% → 2.3% (+0.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 140 → 122 (-18)
58% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 31
73% less capital invested
Capital invested by funds: $383M → $103M (-$280M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$81.9M |
| 2 |
SG Americas Securities
New York
|
+$6.87M |
| 3 |
Renaissance Technologies
New York
|
+$4.5M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.82M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
-$31.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.62M |
| 4 |
Millennium Management
New York
|
-$4.03M |
| 5 |
Morgan Stanley
New York
|
-$3.69M |
CRBP Hedge Fund Activity: Q3 2020 in Review
122 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2020, worth a combined $103M — down 73% from $383M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of CRBP and 13 opened new positions — a net loss of 18 holders — while 33 trimmed existing stakes and 50 added.
The largest buyer was State Street, adding an estimated $81.9M. The largest seller was Carmignac Gestion, exiting entirely with an estimated $31.7M sold.
- 122 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2020, down from 140 in Q2 2020.
- Funds reported $103M of Corbus Pharmaceuticals stock for Q3 2020, down 73% quarter-over-quarter.
- 13 funds opened new Corbus Pharmaceuticals positions in Q3 2020 and 31 closed out, a net change of -18 holders.
- The largest Corbus Pharmaceuticals buyer in Q3 2020 was State Street, an estimated $81.9M added.
- The largest Corbus Pharmaceuticals seller in Q3 2020 was Carmignac Gestion, an estimated $31.7M sold.
Based on aggregated 13F filings for Q3 2020.